

# **Cancer Microbiome Sequencing Market - A Global and Regional Analysis: Focus on Offering, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031**

<https://marketpublishers.com/r/C9A9CCA62C57EN.html>

Date: November 2021

Pages: 187

Price: US\$ 5,250.00 (Single User License)

ID: C9A9CCA62C57EN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

Market Report Coverage - Cancer Microbiome Sequencing

Market Segmentation

Offering– Product (Kits and Assays and Software) and Service

Application– Translational Research and Diagnostics (Colorectal Cancer, Cervical Cancer, Oral Cancer, and Other Cancer Types)

Technology – Next-Generation Sequencing (Sequencing by Synthesis, Sequencing by Ligation, and Other Next-Generation Sequencing Technologies) and Polymerase Chain Reaction

End User – Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, and Other End Users

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, France, U.K., Spain, Italy, Switzerland, and Rest-of-Europe

Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

### Market Growth Drivers

Increasing Emphasis on the Microbiome's Potential in the Field of Cancer

Global Increase in Cancer Prevalence

Decreasing Cost of Sequencing

### Market Challenges

Regulatory Challenges for Direct-to-Consumer (DTC) Companies

Lack of High Complexity Testing Centers

Existing Diagnostic Confidence on Conventional Cancer Diagnostics

### Market Opportunities

Growing Integrative Industry-Academia Collaboration

Massive Scope for Adoption of Cancer Microbiome Sequencing in Developing Nations

### Key Companies Profiled

CD Genomics, Eurofins Scientific, GoodGut, Illumina, Inc., Prescient Medicine Holdings, Inc., Micronoma Inc., Novogene Co., Ltd., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Viome, Inc., Zymo Research Corporation

#### Key Questions Answered in this Report:

How is cancer microbiome sequencing revolutionizing the field of oncology?

What are the major market drivers, challenges, and opportunities in the global cancer microbiome sequencing market?

What are the underlying structures resulting in the emerging trends within the global cancer microbiome sequencing market?

How did the COVID-19 pandemic impact the global cancer microbiome sequencing ecosystem?

What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?

What are the key regulatory implications in developed and developing regions pertaining to the use of cancer microbiome sequencing?

What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?

How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:

- o Offering (product and service)
- o Application (translational research and diagnostics)
- o Technology (next-generation sequencing and polymerase chain reaction)
- o End User (academic and research institutes, pharmaceutical and biotechnology)

companies, hospitals and diagnostic laboratories, and other end users)

o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

What are the growth opportunities for the cancer microbiome sequencing companies in the region of their operation?

Who are the leading players with significant offerings in the global cancer microbiome sequencing market?

Which companies are anticipated to be highly disruptive in the future, and why?

## Market Overview

Our healthcare experts have found the cancer microbiome sequencing industry to be one of the most rapidly evolving and dynamic markets, and the global market for cancer microbiome sequencing is predicted to grow at a CAGR of 20.01% over the forecast period of 2021-2031. The market is driven by certain factors, including increasing emphasis on the microbiome's potential in cancer, global increase in cancer prevalence, and decreasing cost of sequencing.

Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome's potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing. Furthermore, biotechnology companies are focusing on developing cancer microbiome sequencing solutions for applications, including translational research and diagnostics, further supporting researchers and clinicians to unravel insights pertaining to microbiome's influence on cancer manifestation and progression. The development of cancer microbiome sequencing products and services enabled the research community to establish effective strategies for discovering novel cancer biomarkers associated with the microbiome, which could be harnessed for the development of cancer microbiome sequencing products for clinical use.

Within the research report, the market is segmented on the basis of offering, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

## Competitive Landscape

The exponential rise in the number of cancer cases worldwide has created a buzz among the biotechnology companies to further invest in the development of novel diagnostic tools based on microbiome for supporting physicians to offer early cancer detection. Due to the expansive product portfolio and massive geographical presence, Illumina, Inc. has been the leading player in the cancer microbiome sequencing ecosystem.

On the basis of region, North America holds the largest share of the cancer microbiome sequencing market due to the presence of market leaders such as Illumina, Inc. in the U.S. coupled with the significant adoption of high-fidelity cancer microbiome sequencing products and services for translational research. Further, rising fund infusions by the federal organizations and increasing investments for product development, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031. This is majorly attributed to the underlying factors such as an increase in healthcare awareness, steady economy leading to higher focus on research, and widespread adoption of advanced cancer diagnostics, among others.

## Contents

### 1 MARKET

- 1.1 Product Definition
  - 1.1.1 Inclusion and Exclusion
- 1.2 Market Scope
  - 1.2.1 Scope of the Study
  - 1.2.2 Key Questions Answered in the Report
- 1.3 Research Methodology
  - 1.3.1 Global Cancer Microbiome Sequencing Market: Research Methodology
  - 1.3.2 Data Sources
    - 1.3.2.1 Primary Data Sources
    - 1.3.2.2 Secondary Data Sources
  - 1.3.3 Market Estimation Model
  - 1.3.4 Criteria for Company Profiling
- 1.4 Market Overview
  - 1.4.1 Market Definition
  - 1.4.2 Market Footprint and Growth Potential, \$Million, 2020-2031
  - 1.4.3 Impact of COVID-19 on the Global Cancer Microbiome Sequencing Market

### 2 INDUSTRY ANALYSIS

- 2.1 Overview
- 2.2 Legal Requirements and Framework in the U.S.
- 2.3 Legal Requirements and Framework in Europe
- 2.4 Legal Requirements and Framework in Asia-Pacific
  - 2.4.1 China
  - 2.4.2 Japan

### 3 MARKET DYNAMICS

- 3.1 Overview
- 3.2 Iceberg Analysis – Global Cancer Microbiome Sequencing Market
- 3.3 Impact Analysis
- 3.4 Market Drivers
  - 3.4.1 Increasing Emphasis on the Microbiome's Potential in the Field of Cancer
  - 3.4.2 Global Increase in Cancer Prevalence
  - 3.4.3 Decreasing Cost of Sequencing

### 3.5 Market Restraints

3.5.1 Regulatory Challenges for Direct-to-Consumer (DTC) Companies

3.5.2 Lack of High Complexity Testing Centers

3.5.3 Existing Diagnostic Confidence on Conventional Cancer Diagnostics

### 3.6 Market Opportunities

3.6.1 Growing Integrative Industry-Academia Collaboration

3.6.2 Massive Scope for Adoption of Cancer Microbiome Sequencing in Developing Nations

## 4 COMPETITIVE LANDSCAPE

4.1 Overview

4.2 Synergistic Activities

4.3 Product Launches

4.4 Funding

4.5 Product Approval

4.6 Acquisitions

4.7 Market Share Analysis, 2019–2020

4.8 Growth Share Analysis

## 5 OFFERING, \$MILLION, 2020 - 2031

5.1 Overview

5.2 Product

5.2.1 Kits and Assays

5.2.2 Software

5.3 Service

## 6 APPLICATION, \$MILLION, 2020 - 2031

6.1 Overview

6.2 Translational Research

6.3 Diagnostics

6.3.1 Colorectal Cancer (CRC)

6.3.2 Cervical Cancer

6.3.3 Oral Cancer

6.3.4 Other Cancer Types

## 7 TECHNOLOGY, \$MILLION, 2020 - 2031

## 7.1 Overview

## 7.2 Next-Generation Sequencing (NGS)

### 7.2.1 Sequencing by Synthesis (SBS)

### 7.2.2 Sequencing by Ligation (SBL)

### 7.2.3 Other Next-Generation Sequencing (NGS) Technologies

## 7.3 Polymerase Chain Reaction (PCR)

## **8 END USER, \$MILLION, 2020-2031**

## 8.1 Overview

## 8.2 Academic and Research Institutes

## 8.3 Pharmaceutical and Biotechnology Companies

## 8.4 Hospitals and Diagnostic Laboratories

## 8.5 Other End Users

## **9 REGION, \$MILLION, 2020-2031**

## 9.1 Overview

## 9.2 North America

### 9.2.1 U.S.

### 9.2.2 Canada

## 9.3 Europe

### 9.3.1 Germany

### 9.3.2 France

### 9.3.3 U.K.

### 9.3.4 Spain

### 9.3.5 Italy

### 9.3.6 Switzerland

### 9.3.7 Rest-of-Europe

## 9.4 Asia-Pacific

### 9.4.1 China

### 9.4.2 Japan

### 9.4.3 India

### 9.4.4 Australia

### 9.4.5 South Korea

### 9.4.6 Singapore

### 9.4.7 Rest-of-Asia-Pacific

## 9.5 Latin America



- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest-of-Latin America (RoLA)
- 9.6 Rest-of-the-World

## **10 COMPANY PROFILES**

- 10.1 Overview
- 10.2 CD Genomics
  - 10.2.1 Company Overview
  - 10.2.2 Role of CD Genomics in the Global Cancer Microbiome Sequencing Market
  - 10.2.3 SWOT Analysis
- 10.3 Eurofins Scientific
  - 10.3.1 Company Overview
  - 10.3.2 Role of Eurofins Scientific in the Global Cancer Microbiome Sequencing Market
  - 10.3.3 Financials
  - 10.3.4 SWOT Analysis
- 10.4 GoodGut
  - 10.4.1 Company Overview
  - 10.4.2 Role of GoodGut in the Global Cancer Microbiome Sequencing Market
  - 10.4.3 SWOT Analysis
- 10.5 Illumina, Inc.
  - 10.5.1 Company Overview
  - 10.5.2 Role of Illumina, Inc. in the Global Cancer Microbiome Sequencing Market
  - 10.5.3 Financials
  - 10.5.4 Key Insights About Financial Health of the Company
  - 10.5.5 SWOT Analysis
- 10.6 Prescient Medicine Holdings, Inc.
  - 10.6.1 Company Overview
  - 10.6.2 Role of Prescient Medicine Holdings, Inc. in the Global Cancer Microbiome Sequencing Market
  - 10.6.3 SWOT Analysis
- 10.7 Micronoma Inc.
  - 10.7.1 Company Overview
  - 10.7.2 Role of Micronoma Inc. in the Global Cancer Microbiome Sequencing Market
  - 10.7.3 SWOT Analysis
- 10.8 Novogene Co., Ltd.
  - 10.8.1 Company Overview
  - 10.8.2 Role of Novogene Co., Ltd. in the Global Cancer Microbiome Sequencing

## Market

### 10.8.3 SWOT Analysis

## 10.9 Oxford Nanopore Technologies plc.

### 10.9.1 Company Overview

### 10.9.2 Role of Oxford Nanopore Technologies plc. in the Global Cancer Microbiome

## Sequencing Market

### 10.9.3 Financials

### 10.9.4 Key Insights About Financial Health of the Company

### 10.9.5 SWOT Analysis

## 10.1 OraSure Technologies, Inc.

### 10.10.1 Company Overview

### 10.10.2 Role of OraSure Technologies, Inc. in the Global Cancer Microbiome

## Sequencing Market

### 10.10.3 Financials

### 10.10.4 Key Insights About Financial Health of the Company

### 10.10.5 SWOT Analysis

## 10.11 Pacific Biosciences of California, Inc.

### 10.11.1 Company Overview

### 10.11.2 Role of Pacific Biosciences of California, Inc. in the Global Cancer Microbiome

## Sequencing Market

### 10.11.3 Financials

### 10.11.4 Key Insights About Financial Health of the Company

### 10.11.5 SWOT Analysis

## 10.12 Psomagen, Inc.

### 10.12.1 Company Overview

### 10.12.2 Role of Psomagen, Inc. in the Global Cancer Microbiome Sequencing Market

### 10.12.3 Financials

### 10.12.4 Key Insights About Financial Health of the Company

### 10.12.5 SWOT Analysis

## 10.13 QIAGEN N.V.

### 10.13.1 Company Overview

### 10.13.2 Role of QIAGEN N.V. in the Global Cancer Microbiome Sequencing Market

### 10.13.3 Financials

### 10.13.4 Key Insights About Financial Health of the Company

### 10.13.5 SWOT Analysis

## 10.14 Thermo Fisher Scientific Inc.

### 10.14.1 Company Overview

### 10.14.2 Role of Thermo Fisher Scientific Inc. in the Global Cancer Microbiome

## Sequencing Market

10.14.3 Financials

10.14.4 Key Insights About Financial Health of the Company

10.14.5 SWOT Analysis

10.15 Viome, Inc.

10.15.1 Company Overview

10.15.2 Role of Viome, Inc. in the Global Cancer Microbiome Sequencing Market

10.15.3 SWOT Analysis

10.16 Zymo Research Corporation

10.16.1 Company Overview

10.16.2 Role of Zymo Research Corporation in the Global Cancer Microbiome  
Sequencing Market

10.16.3 SWOT Analysis

## List Of Figures

### LIST OF FIGURES

Figure 1: Annual NIH Funding for Microbiome Research, \$Million, FY2007-FY2016

Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Cancer Microbiome Sequencing Market

Figure 3: Global Cancer Microbiome Sequencing Market (by Offering), \$Million, 2020 and 2031

Figure 4: Global Cancer Microbiome Sequencing Market (by Application), \$Million, 2020 and 2031

Figure 5: Global Cancer Microbiome Sequencing Market (by Technology), 2020 and 2021

Figure 6: Global Cancer Microbiome Sequencing Market (by End User), \$Million, 2020 and 2031

Figure 7: Global Cancer Microbiome Sequencing Market Snapshot

Figure 8: Global Cancer Microbiome Sequencing Market: Segmentation

Figure 9: Global Cancer Microbiome Sequencing Market: Methodology

Figure 10: Primary Research Methodology

Figure 11: Bottom-Up Approach (Segment-Wise Analysis)

Figure 12: Top-Down Approach (Segment-Wise Analysis)

Figure 13: Global Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 14: Global Cancer Microbiome Sequencing Market: COVID-19 Impact Analysis

Figure 15: Assessment of Commercialization Strategy in China

Figure 16: Assessment of Commercialization Strategy in Japan

Figure 17: Iceberg Analysis – Global Cancer Microbiome Sequencing Market

Figure 18: Global Cancer Burden, 2018

Figure 19: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)

Figure 20: Share of Key Developments and Strategies, January 2018-September 2021

Figure 21: Share of Synergistic Activities (by Company), January 2018-November 2021

Figure 22: Number of Product Launches (by Company), January 2018–November 2021

Figure 23: Share of Funding Activities (by Company), January 2018-November 2021

Figure 24: Share of Product Approvals (by Company), January 2018-November 2021

Figure 25: Market Share Analysis for Global Cancer Microbiome Sequencing Market, \$Million, 2019 and 2020

Figure 26: Growth Share Analysis for Global Cancer Microbiome Sequencing Market (by Company), 2020

Figure 27: Global Cancer Microbiome Sequencing Market (by Offering)

Figure 28: Global Cancer Microbiome Sequencing Market (by Offering), 2020 and 2031

Figure 29: Global Cancer Microbiome Sequencing Market (by Product), \$Million, 2020-2031

Figure 30: Global Cancer Microbiome Sequencing Market (by Product), \$Million, 2020-2031

Figure 31: Global Cancer Microbiome Sequencing Market (Kits and Assays), \$Million, 2020-2031

Figure 32: Global Cancer Microbiome Sequencing Market (Software), \$Million, 2020-2031

Figure 33: Global Cancer Microbiome Sequencing Market (Service), \$Million, 2020-2031

Figure 34: Global Cancer Microbiome Sequencing Market (by Application)

Figure 35: Global Cancer Microbiome Sequencing Market (by Application), \$Million, 2020–2031

Figure 36: Global Cancer Microbiome Sequencing Market (Translational Research), \$Million, 2020-2031

Figure 37: Global Cancer Microbiome Sequencing Market (Diagnostics), \$Million, 2020-2031

Figure 38: Global Cancer Microbiome Sequencing Market (by Diagnostics), 2020 and 2031

Figure 39: Global Cancer Microbiome Sequencing Market (CRC), \$Million, 2020-2031

Figure 40: Global Cancer Microbiome Sequencing Market (Cervical Cancer), \$Million, 2020-2031

Figure 41: Global Cancer Microbiome Sequencing Market (Oral Cancer), \$Million, 2020-2031

Figure 42: Global Cancer Microbiome Sequencing Market (Other Cancer Types), \$Million, 2020-2031

Figure 43: Global Cancer Microbiome Sequencing Market (by Technology)

Figure 44: Global Cancer Microbiome Sequencing Market (by Technology), 2020 and 2021

Figure 45: Global Cancer Microbiome Sequencing Market (by Next-Generation Sequencing), \$Million, 2020-2031

Figure 46: Global Cancer Microbiome Sequencing Market (Sequencing by Synthesis), \$Million, 2020-2031

Figure 47: Global Cancer Microbiome Sequencing Market (Sequencing by Ligation), \$Million, 2020-2031

Figure 48: Global Cancer Microbiome Sequencing Market (Other NGS Technologies), \$Million, 2020-2031

Figure 49: Global Cancer Microbiome Sequencing Market (Polymerase Chain

Reaction), \$Million, 2020-2031

Figure 50: Global Cancer Microbiome Sequencing Market (by End User)

Figure 51: Global Cancer Microbiome Sequencing Market (by End User), \$Million, 2020–2031

Figure 52: Global Cancer Microbiome Sequencing Market (Academic and Research Institutions), \$Million, 2020-2031

Figure 53: Global Cancer Microbiome Sequencing Market (Pharmaceutical and Biotechnology Companies), \$Million, 2020-2031

Figure 54: Global Cancer Microbiome Sequencing Market (Hospitals and Diagnostic Laboratories), \$Million, 2020-2031

Figure 55: Global Cancer Microbiome Sequencing Market (Other End Users), \$Million, 2020-2031

Figure 56: Global Cancer Microbiome Sequencing (by Region): Market Snapshot

Figure 57: Global Cancer Microbiome Sequencing Market (by Region), \$Million, 2020-2031

Figure 58: Global Cancer Microbiome Sequencing Market (by Region), 2020 and 2031

Figure 59: North America Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 60: North America Cancer Microbiome Sequencing Market (by Country), \$Million, 2020-2031

Figure 61: U.S. Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 62: Canada Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 63: Europe Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 64: Europe Cancer Microbiome Sequencing Market (by Country), \$Million, 2020–2031

Figure 65: Germany Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 66: France Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 67: U.K. Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 68: Spain Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 69: Italy Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 70: Switzerland Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 71: Rest-of-Europe Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 72: Asia-Pacific Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 73: APAC Cancer Microbiome Sequencing Market (by Country), \$Million, 2020-2031

Figure 74: China Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 75: Japan Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 76: India Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 77: Australia Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 78: South Korea Cancer Microbiome Sequencing Market, \$Million, 2020-2031



Figure 79: Singapore Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 80: RoAPAC Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 81: Latin America Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 82: Latin America Cancer Microbiome Sequencing Market (by Country), \$Million, 2020-2031

Figure 83: Brazil Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 84: Mexico Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 85: Rest-of-Latin America Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 86: Rest-of-the-World Cancer Microbiome Sequencing Market, \$Million, 2020-2031

Figure 87: Total Number of Companies Profiled

Figure 88: CD Genomics: Product Portfolio

Figure 89: CD Genomics: SWOT Analysis

Figure 90: Eurofins Scientific: Portfolio

Figure 91: Eurofins Scientific: Overall Financials, 2018-2020

Figure 92: Eurofins Scientific: Revenue (by Region), 2018-2020

Figure 93: Eurofins Scientific: SWOT Analysis

Figure 94: GoodGut: Portfolio

Figure 95: GoodGut: SWOT Analysis

Figure 96: Illumina, Inc.: Product Portfolio

Figure 97: Illumina, Inc.: Overall Financials, 2018-2020

Figure 98: Illumina, Inc.: Revenue (by Business Segment), 2018–2020

Figure 99: Illumina, Inc.: Revenue (by Region), 2018–2020

Figure 100: Illumina, Inc.: R&D Expenditure, 2018-2020

Figure 101: Illumina, Inc.: SWOT Analysis

Figure 102: Prescient Medicine Holdings, Inc.: Product Portfolio

Figure 103: Prescient Medicine Holdings, Inc.: SWOT Analysis

Figure 104: Micronoma Inc.: Product Portfolio

Figure 105: Micronoma Inc.: SWOT Analysis

Figure 106: Novogene Co., Ltd.: Product Portfolio

Figure 107: Novogene Co., Ltd.: SWOT Analysis

Figure 108: Oxford Nanopore Technologies plc.: Product Portfolio

Figure 109: Oxford Nanopore Technologies plc.: Overall Financials, 2018-2020

Figure 110: Oxford Nanopore Technologies plc.: Revenue (by Business Segment), 2018–2020

Figure 111: Oxford Nanopore Technologies plc.: Revenue (by Region), 2018–2020

Figure 112: Oxford Nanopore Technologies plc.: R&D Expenditure, 2018 - 2020

Figure 113: Oxford Nanopore Technologies plc.: SWOT Analysis

- Figure 114: OraSure Technologies, Inc.: Product Portfolio
- Figure 115: OraSure Technologies, Inc.: Overall Financials, 2018-2020
- Figure 116: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
- Figure 117: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020
- Figure 118: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020
- Figure 119: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
- Figure 120: OraSure Technologies, Inc.: SWOT Analysis
- Figure 121: Pacific Biosciences of California, Inc.: Product Portfolio
- Figure 122: Pacific Biosciences of California, Inc.: Overall Financials, 2018-2020
- Figure 123: Pacific Biosciences of California, Inc.: Revenue (by Business Segment), 2018–2020
- Figure 124: Pacific Biosciences of California, Inc.: Revenue (by Region), 2018–2020
- Figure 125: Pacific Biosciences of California, Inc.: R&D Expenditure, 2018-2020
- Figure 126: Pacific Biosciences of California, Inc.: SWOT Analysis
- Figure 127: Psomagen, Inc.: Portfolio
- Figure 128: Psomagen, Inc.: Overall Financials, 2018-2020
- Figure 129: Psomagen, Inc.: Revenue (by Business Segment), 2018–2020
- Figure 130: Psomagen, Inc.: Revenue (by Region), 2019–2020
- Figure 131: Psomagen, Inc.: R&D Expenditure, 2018-2020
- Figure 132: Psomagen, Inc.: SWOT Analysis
- Figure 133: QIAGEN N.V.: Product Portfolio
- Figure 134: QIAGEN N.V.: Overall Financials, 2018-2020
- Figure 135: QIAGEN N.V.: Revenue (by Business Segment), 2018–2020
- Figure 136: QIAGEN N.V.: Revenue (by Region), 2018–2020
- Figure 137: QIAGEN N.V.: R&D Expenditure, 2018-2020
- Figure 138: QIAGEN N.V.: SWOT Analysis
- Figure 139: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 140: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
- Figure 141: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018–2020
- Figure 142: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018–2020
- Figure 143: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
- Figure 144: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 145: Viome, Inc.: Product Portfolio
- Figure 146: Viome, Inc.: SWOT Analysis
- Figure 147: Zymo Research Corporation: Product Portfolio
- Figure 148: Zymo Research Corporation: SWOT Analysis



## List Of Tables

### LIST OF TABLES

Table 1: Likert Scale

Table 2: Impact Analysis of Market Drivers

Table 3: Impact Analysis of Market Restraints

Table 4: North America: Market Dynamics

Table 5: Europe: Market Dynamics

Table 6: APAC: Market Dynamics

Table 7: Latin America: Market Dynamics

## I would like to order

Product name: Cancer Microbiome Sequencing Market - A Global and Regional Analysis: Focus on Offering, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/C9A9CCA62C57EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9A9CCA62C57EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970